UNSPSC 51312508: Tiacrilast sodium

This classification denotes a histamine-1 receptor antagonist C12H9N2O3S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4PG8A6UTDX, chemically known as sodium (e)-6-(methylthio)-4-oxo-3(4h)-quinazolineacrylate, monohydrate, but more generally known as tiacrilast sodium, which bears US NIH Compound Identifier 23665632. Most nations, for tariff and trade purposes, schedule tiacrilast sodium under HS 29335995 and SITC 51576. As of Q4 2014, TIACRILAST SODIUM remains US FDA's Preferred Term for this commodity.

Tiacrilast sodium bears US NLM identifiers UMLS ID C2348786 and NCI Concept Code C72862. SMILES: CSC1CCC2C(C1)C(=O)N(CN2)/C=C/C(=O)[O-].O.[NA+].

UNSPSC 51312508 Tiacrilast sodium is a Commodity code representing pharmaceutical products purchased by state and local health authorities, though the recent solicitation activity under this code shows a significant mismatch with the nominal product scope. Seminole County, Florida's IFB60459723LAS solicitation, posted June 30, 2026, seeks Naloxone and Safe Drug Deactivation Systems rather than tiacrilast sodium—a clear divergence from the code's stated pharmaceutical definition. The county is procuring 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building. Vendors must submit bids electronically through the county's e-Procurement Portal, include all shipping and delivery costs, and comply with drug-free workplace certification and E-Verify requirements. The contract carries a two-year initial term with an optional one-year renewal and includes a three-month probationary period allowing termination at will. Insurance requirements include workers' compensation, commercial general liability, and professional liability coverage. Potential FEMA funding introduces additional federal compliance obligations under the Clean Air Act and Federal Water Pollution Control Act.

The code shows limited recent state and local activity aligned with its pharmaceutical definition. Seminole County, Florida represents the primary issuing body with recent documented procurement. The response deadline for the Seminole County IFB was July 26, 2023—substantially before the current date of October 20, 2026—indicating that the summarized opportunity is now closed. No other state or local opportunities under UNSPSC 51312508 appear in the recent record, and the single documented solicitation procures harm-reduction and drug-management products rather than tiacrilast sodium specifically. Businesses pursuing opportunities under this code should note that actual state and local buying activity diverges materially from the code's nominal scope, and current market activity in this category remains sparse.